Imuran, also called azathioprine, is a medication with the active ingredient azathioprine. It is used to help prevent the body’s immune system from rejecting a transplanted organ. Imuran is also used to treat certain autoimmune diseases, where the immune system attacks the body’s own tissues.
Typically, Imuran is priced from £0.69 up to £0.96 per pills. Variance in price is rooted in the pack’s volume and the concentration of active entities (30 or 360 mg).
Imuran contains azathioprine as its active ingredient, an immunosuppressive medication. Azathioprine is a derivative of 6-mercaptopurine. It works by inhibiting purine synthesis, necessary for the proliferation of cells, particularly leukocytes.
The typical starting dose for adults is 1-3 mg/kg/day, adjusted based on clinical response and blood work. The maintenance dose usually ranges between 1-2.5 mg/kg/day. For children, dosage is often individualized based upon body weight and specific condition being treated.
Imuran is used for preventing organ transplant rejection, primarily in renal transplants. It is also prescribed for autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.
After oral administration, azathioprine is well absorbed in the gastrointestinal tract. Its bioavailability ranges from 30% to 80%. It is extensively metabolized by the liver and demonstrates a plasma half-life of approximately 5 hours. Excretion is primarily through the kidneys.
Allopurinol, often used to treat gout, can increase azathioprine toxicity by inhibiting its metabolism. Concurrent use with ACE inhibitors, such as lisinopril, can enhance the risk of haematological toxicity. Warfarin’s anticoagulant effect may be reduced when taken with Imuran.
Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Bone marrow suppression, including leukopenia, thrombocytopenia, and anemia, is a significant risk. Skin rashes, hepatotoxicity, and increased risk of infections are also reported.
Regular complete blood counts (CBC) are essential, particularly during the initial months of therapy. Liver function tests should be conducted frequently to detect hepatotoxicity early. Patients should also be monitored for signs of infections due to immunosuppression.
In elderly patients, start with the lower end of the dosing range due to potentially decreased renal function. During pregnancy, Imuran should only be used if the potential benefit justifies the potential risk to the fetus. Lactating mothers are usually advised against using the drug as azathioprine and its metabolites are excreted into breast milk.
Azathioprine inhibits several enzymatic pathways in DNA, RNA, and protein synthesis. It primarily affects rapidly proliferating cells, such as T cells and B cells, thus reducing the immune response, which is particularly beneficial in preventing organ rejection and in autoimmune diseases.
Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites. It should not be administered to patients with a current diagnosis of malignancy. Those who have previously experienced serious toxicities related to purine antimetabolites should avoid this medication.
Store Imuran at room temperature, away from excessive heat and moisture. It should be kept in tightly closed containers, out of reach of children and pets. Avoid exposure to direct sunlight.
The duration of Imuran therapy is often long-term, particularly for chronic autoimmune conditions and organ transplantation. Dosage adjustments may be necessary over time based on therapeutic response and side effects.
If a dose is missed, it should be taken as soon as remembered. If it is nearly time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double doses to make up for a missed one.
Imuran should be handled with care, particularly in healthcare settings involving direct contact. After handling, wash hands thoroughly. Dispose of expired or unused medication through take-back programs or as per local regulations.
Healthcare professionals preparing and dispensing Imuran should wear appropriate protective clothing like gloves. Dispense each vial or tablet with appropriate labeling, and provide the patient with a detailed usage guide including any necessary administration instructions.
Imuran is available as a brand-name drug and has generic versions labeled as azathioprine. Both have similar efficacy and safety profiles, but the cost may differ significantly between the brand and generic options.
Imuran is available in oral tablet forms and as an injectable solution. Tablets are typically available in 50 mg strengths, while the injectable solution is supplied in varying concentrations suited for intravenous administration.
Oral administration is the most common route for taking Imuran, though IV administration may be used in clinical settings where rapid onset of action is required or when oral administration is not feasible.
Besides Imuran, azathioprine is marketed under brand names such as Azasan. These brands are equivalent in terms of dosage forms and therapeutic effects, though availability may vary by region.
For elderly patients, careful dose selection is essential, often starting at the lower end of the dosing range. Monitor renal function as age-related renal function decline may affect drug elimination and increase risk of adverse effects.
While Imuran is used in pediatric patients for conditions such as autoimmune diseases and organ transplantation, dosages are carefully calculated based on body weight and clinical indications. Continuous monitoring for side effects is crucial.
For chronic conditions, maintenance therapy with Imuran aims to achieve disease remission or prevent organ rejection while minimizing adverse effects. This requires regular monitoring and possible dose adjustments.
Patients should be informed about the need for regular blood tests and the importance of promptly reporting any signs of infection, unusual bleeding or bruising, and jaundice. They should understand the importance of adhering to dosage schedules and not discontinuing therapy without consulting their healthcare provider.
Imuran may interfere with certain laboratory tests. Inform laboratory personnel about the use of azathioprine when undergoing blood tests, as it may alter results such as liver function tests and complete blood counts.
Though primarily used for preventing transplant rejection and autoimmune diseases, Imuran is sometimes used off-label for conditions like idiopathic thrombocytopenic purpura (ITP) and myasthenia gravis based on clinical judgment and empirical evidence.
Patients with renal or hepatic impairment may require dosage adjustments. Monitoring organ function tests can guide dose modifications to maintain therapeutic efficacy while minimizing toxicity.